Skip to Main Content

The Trump administration’s move to pick five companies as finalists in the quest to develop a vaccine for the novel coronavirus has set off a pharmaceutical Space Race in the industry. And for each of the five firms involved, there’s a lot at stake: reputation, a boon to national pride, maybe even a rebuke to voluble skeptics.

Coming in first could help, too.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

Comments are closed.